cbl-b-inhibitor
(2)
Nurix Therapeutics
Nurix Therapeutics is a clinical-stage biopharmaceutical company in San Francisco pioneering targeted protein degradation - medicines that destroy disease-causing proteins rather than merely blocking them. Built on its DELigase discovery engine that harnesses the cell's ubiquitin-proteasome system and DNA-encoded library screening, Nurix is advancing a pipeline of degraders and degrader antibody conjugates for cancer and autoimmune disease, led by the BTK degrader bexobrutideg (NX-5948). The company is partnered with Roche, Sanofi, Gilead, and Pfizer (via Seagen) and trades on Nasdaq under NRIX.
Jonathan Montagu
Jonathan Montagu is the co-founder and CEO of HotSpot Therapeutics, a Boston biotech he started in 2017 to chase what the industry long called undruggable. His bet: target the 'natural hotspots' that evolution built into proteins to switch them on and off, and you can make small-molecule medicines with precision the old playbook couldn't reach. A chemist trained at Oxford, Scripps and Cancer Research UK with a Stanford MBA, he previously did the dealmaking that put Nimbus Therapeutics and Concert Pharmaceuticals on the map, including a $1B GSK transaction. Under him HotSpot has raised roughly $210M and pushed its Smart Allostery platform into the clinic, presenting first-in-human Phase 1 data on its CBL-B inhibitor HST-1011 at ESMO 2024.